Singapore markets closed
Straits Times Index
3,255.54 +16.51 (+0.51%) S&P 500
3,962.21 -15.32 (-0.39%) Dow
32,431.21 -0.87 (-0.00%) Nasdaq
11,663.86 -104.98 (-0.89%) Bitcoin USD
26,939.65 -397.46 (-1.45%) CMC Crypto 200
590.28 +347.60 (+143.23%)
AZN Jul 2023 67.500 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 01:13PM EDT. Market open.
| Previous close | 5.0000 |
| Open | 5.0000 |
| Bid | 4.8500 |
| Ask | 5.0000 |
| Strike | 67.50 |
| Expiry date | 2023-07-21 |
| Day's range | 5.0000 - 5.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 657 |
- Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
- Business Wire
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1
- Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
© 2023 Yahoo. All rights reserved.
